Company intelligence / Profile preview

Azralez Pharmaceuticals

Raleigh, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Azralez Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of high-impact therapies for gastrointestinal disorders. The company is best known for acquiring the rights to Zelnorm (tegaserod), a 5-HT4 receptor agonist indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult women. Founded by a team of experienced industry executives, Azralez aims to revitalize established brands and address unmet needs in the GI space. The company operates with a lean, commercial-stage model, leveraging strategic partnerships for manufacturing and distribution.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Alfasigma USA

Beyond the preview

Go deeper on Azralez Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azralez Pharmaceuticals.

Explore the full profile